silybin has been researched along with Disease Models, Animal in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (15.38) | 29.6817 |
| 2010's | 46 (58.97) | 24.3611 |
| 2020's | 20 (25.64) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chen, W; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Wang, C | 1 |
| Huang, L; Huo, Q; Qi, Y; Shi, Y; Sui, H; Zhao, L | 1 |
| AbouZid, SF; Ahmed, OM; Ali, TM; Almoiliqy, M; An, S; Anggraeni, AT; Bailón-García, E; Bueno-López, A; Buyze, J; Chen, DQ; Chen, X; Davó-Quiñonero, A; De Weggheleire, A; Ding, Z; El-Kalaawy, AM; Elesawy, BH; Francque, S; Gao, F; Guo, Y; Juan-Juan, J; Li, S; Li, Y; Lin, Y; Liu, X; Liu, Z; Lozano-Castelló, D; Lu, X; Lynen, L; Meng, Q; Peng, J; Ran, Y; Razali, MH; Rodríguez, SL; Shen, MJ; Soedarsono, S; Soeprijanto, B; Su, W; Sun, P; Tang, AL; Thai, S; Tian, G; Topîrceanu, A; van Griensven, J; Wang, H; Wang, Y; Wen, J; Xi, J; Xiong, MC; Yang, S; Yang, X; Yassin, NYS; Ye, L; Yusoff, M; Zhang, GQ; Zhang, Y | 1 |
| Abazari, O; Abbasi, M; Ajami Khiyavi, H; Ebrahimi, M; Eskandari, Y; Faisal Faiz, A; Khosh Ravesh, R; Maleki, N; Norbakhsh, R; Panji, M; Safizadeh, F; Salehiyeh, S; Sharbati, A | 1 |
| Li, TL; Tao, ZS; Wei, S | 1 |
| Chen, W; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Kang, Y; Liu, P; Liu, W; Mizuno, K; Qiu, Z; Wang, C | 1 |
| Cao, L; Ding, C; Hao, H; He, T; Shuai, Y; Wang, Y; Wu, J; Xie, Z; Xu, W; Zhang, C; Zhang, S | 1 |
| Chen, W; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Kang, Y; Liu, P; Liu, W; Mizuno, K; Qiu, Z; Wang, C; Wang, X | 1 |
| Chavarría, A; García, E; Meza, C; Pérez-Ramírez, DJ; Ramírez-Carreto, RJ; Rodríguez-López, BE; Santamaría, A; Zaldívar-Machorro, VJ | 1 |
| Chen, D; Feng, J; Gong, T; Guo, C; He, Q; Li, J; Song, X; Tan, T; Tan, Y; Yang, Q | 1 |
| Liu, J; Liu, K; Liu, M; Wang, Y; Zhou, S; Zhu, F | 1 |
| Aa, J; Sun, R; Wang, G; Wei, Q; Xie, Y; Xu, D; Zhang, B | 1 |
| Ababneh, Q; Alsaggar, M; Alzoubi, KH; Bdour, S; El-Elimat, T; Qinna, N | 1 |
| Ding, Z; Li, Y; Liu, R; Wang, Q; Zang, Y; Zhang, G; Zhang, X | 1 |
| He, K; Jiang, M; Liu, Q; Qiu, T; Sun, J; Zhang, X; Zheng, H | 1 |
| Gholami, M; Khonakdar-Tarsi, A; Qajari, NM; Shafaroudi, MM | 1 |
| Furutani, Y; Hayama, E; Kawaguchi, N; Nakanishi, T; Sugiyama, H; Tsuji, K; Zhang, T | 1 |
| Anbardar, MH; Chavoshy, F; Tamaddon, AM; Zadeh, BSM | 1 |
| Dong, Y; Luo, J; Ma, L; Zeng, Y; Zhang, Z | 1 |
| Chen, Y; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, P; Liu, W; Liu, X; Mizuno, K; Wang, C | 1 |
| Cao, S; Wang, B; Wang, Y; Wu, D; Zhang, B | 1 |
| Chen, CL; Chen, JT; Chen, YH; Liang, CM; Lu, DW; Tai, MC | 1 |
| Anagnostopoulos, C; Christodoulou, E; Kakazanis, Z; Kostomitsopoulos, N; Kyriakopoulos, G; Lambropoulou, M; Simopoulos, CE; Tsalikidis, C; Tsaroucha, AK; Valsami, G | 1 |
| Cui, L; Hattori, S; Hayashi, T; Ikejima, T; Liu, B; Liu, W; Song, X; Tashiro, SI; Ushiki-Kaku, Y; Xu, F; Zhou, B | 1 |
| Bai, D; Gan, S; Jin, G; Liu, X; Ren, L; Sun, Y; Yang, Z; Yin, S; Zhu, Q; Zou, D | 1 |
| Anagnostopoulos, C; Betsou, A; Christodoulou, E; Falidas, E; Kostomitsopoulos, N; Lambropoulou, M; Pitiakoudis, M; Simopoulos, CE; Tsaroucha, AK; Valsami, G | 1 |
| He, XK; Hong, T; Li, J; Liu, DH; Tong, WW; Wang, C; Xu, WD; Zhang, C | 1 |
| Li, YJ; Niu, WM; Wei, XM; Wu, YM; Yang, LD; Yang, Q; Zhang, K; Zhao, MG; Zheng, KY | 1 |
| Bazer, FW; Ham, J; Kim, J; Lim, W; Song, G | 1 |
| Ou, Q; Wang, S; Weng, Y; Wu, X; Zhang, F; Zhao, Y; Zhou, J | 1 |
| Bui, QD; Chi, SC; Ho, XH; Nguyen, HA; Nguyen, TD; Pham, DV; Tran, CS; Tung, NT | 1 |
| Han, W; Li, W; Lv, X; Wang, H; Zhao, X | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Jain, A; Orlicky, DJ; Rigby, C | 1 |
| Furutani, Y; Hayama, E; Kawaguchi, K; Kawaguchi, N; Nakanishi, T; Tanaka, T; Yoshihara, K; Zhang, T | 1 |
| Bai, D; Chen, X; Cui, Y; Jin, G; Li, W; Liu, X; Sun, Y; Wang, M; Zhang, D; Zhang, L; Zhao, L; Zhu, L; Zhu, Q | 1 |
| Ji, HF; Li, XY; Liu, L; Shen, L | 1 |
| Huso, DL; Karim, BO; Liu, G; Rhee, KJ; Zheng, D | 1 |
| Agarwal, R; Mateen, S; Raina, K | 1 |
| Nambiar, D; Singh, RP | 1 |
| Carratù, MR; de Bari, O; Diogo, CV; Ferri, D; Grattagliano, I; Liquori, A; Mastrodonato, M; Oliveira, PJ; Persichella, M; Portincasa, P; Wang, DQ | 1 |
| Chang, YH; Chen, CL; Chen, JT; Chen, YH; Chien, KH; Liang, CM; Lu, DW; Tai, MC | 1 |
| Abboud, HE; Cavaglieri, RC; Fanti, P; Gorin, Y; Khazim, K | 1 |
| Bouderba, S; Detaille, D; Koceïr, EA; Sanchez-Martin, C; Villanueva, GR | 1 |
| Muthumani, M; Prabu, SM | 1 |
| Ding, M; Duan, W; Feng, W; Jin, Z; Liang, Z; Nie, Y; Wang, N; Yan, J; Yang, J; Yang, Y; Zhang, S | 1 |
| Choi, MS; Jeon, MT; Jung, UJ; Kim, SR | 1 |
| Agarwal, C; Agarwal, R; Biedermann, D; Deep, G; Kren, V; Tilley, C; Valentová, K; Wempe, MF | 1 |
| Buchfelder, M; Freiburger, L; Hausch, F; Kozany, C; Paez-Pereda, M; Riebold, M; Sattler, M; Stalla, GK | 1 |
| Chun, HJ; Lee, J; Lee, Y; Park, HR | 1 |
| Chun, HJ; Jung, YS; Lee, J; Lee, KM; Lee, Y | 1 |
| Ali, SO; Darwish, HA; Ismail, NA | 1 |
| Akamatsu, S; Canini, L; Chayama, K; Dahari, H; DebRoy, S; Hayes, CN; Hiraga, N; Imamura, M; Perelson, AS; Persiani, S; Pohl, RT; Tateno, C; Uprichard, SL | 1 |
| Arslan, S; Ekin, N; İbiloğlu, İ; Kaplan, İ; Şenateş, E; Uçmak, F | 1 |
| Hu, WY; Li, XX; Ma, XH; Sun, H; Sun, TT; Zhou, WY | 1 |
| Agarwal, R; Chittezhath, M; Deep, G; Raina, K; Rajamanickam, S; Singh, RP | 1 |
| Galanopoulou, P; Giannioti, K; Liapi, C; Mikros, E; Papalois, A; Theocharis, S; Zira, A | 1 |
| Cui, W; Gu, F; Hu, KQ | 1 |
| Choi, YH; Yan, GH | 1 |
| Felix, AJ; Nalini, N; Sangeetha, N | 1 |
| Agarwal, R; Kaur, M; Rajamanickam, S; Singh, RP; Velmurugan, B | 2 |
| Fan, SM; Huang, H; Ikejima, T; Jiang, YY; Onodera, S; Tashiro, S; Wang, HJ; Wei, XF; Yang, Y; Zang, LH | 1 |
| Abdollahi, M; Baeeri, M; Esmaily, H; Miroliaee, AE; Vaziri-Bami, A | 1 |
| Kamat, PK; Nath, C; Shukla, R; Tota, S | 1 |
| Minhu, C; Yao, J; Zhi, M | 1 |
| Galvano, F; Li Volti, G; Mangiameli, A; Salamone, F; Salomone, S; Siarkos, I; Sorrenti, V; Urso, V | 1 |
| Di Cesare Mannelli, L; Failli, P; Ghelardini, C; Zanardelli, M | 1 |
| Barbagallo, I; Cappello, F; Galvano, F; Li Volti, G; Mangiameli, A; Salamone, F | 1 |
| Bour, G; Bousserouel, S; Gossé, F; Kauntz, H; Marescaux, J; Raul, F | 1 |
| Bannwart, CF; Medeiros, LT; Nakaira-Takahagi, E; Peraçoli, JC; Peraçoli, MT; Romão, M; Silva, MG; Souza, CO; Weel, IC | 1 |
| Cheng, HW; Cheng, YW; Huang, WK; Li, CH; Liao, PL; Lin, CH; Tse, LS | 1 |
| Lubet, RA; Tan, Q; Wang, Y; Yan, Y; You, M | 1 |
| Agarwal, R; Chittezhath, M; Deep, G; Dwyer-Nield, LD; Kaur, M; Malkinson, AM; Singh, RP | 1 |
| Choi, IH; Choi, YH; Chung, HY; Jeong, YI; Kim, GY; Kim, HK; Kim, SG; Lee, CM; Lee, JS; Lee, TH; Na, YJ; Park, NC; Park, YM; Suh, DS; Yoon, MS | 1 |
| Betten, DP; Clark, RF; Favata, M; Hernandez, M; Richardson, WH; Riffenburgh, RH; Tanen, DA; Tong, TC | 1 |
| Agarwal, R; Blouin, MJ; Cohen, P; Deep, G; Glodé, LM; Greenberg, NM; Hwang, D; Majeed, N; Pollak, MN; Raina, K; Singh, RP; Varghese, L | 1 |
| Brault, A; Haddad, PS; Haddad, Y; Ligeret, H; Vallerand, D | 1 |
2 review(s) available for silybin and Disease Models, Animal
| Article | Year |
|---|---|
Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoprevention; Disease Models, Animal; Epigenesis, Genetic; Humans; Lung Neoplasms; Silybin; Silymarin | 2013 |
Advances in prostate cancer chemoprevention: a translational perspective.
Topics: Androgen Antagonists; Animals; Anticarcinogenic Agents; Antioxidants; Azasteroids; Carotenoids; Chemoprevention; Clinical Trials as Topic; Curcumin; Disease Models, Animal; Dutasteride; Finasteride; Flavonoids; Genistein; Humans; Lycopene; Male; Phytochemicals; Polyphenols; Prostate; Prostatic Neoplasms; Risk Factors; Selenium; Silybin; Silymarin; Tea; Vitamin E | 2013 |
76 other study(ies) available for silybin and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Depression; Disease Models, Animal; Humans; Interferon Regulatory Factor-3; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Quality of Life; Silybin | 2021 |
Biomimetic silibinin-loaded macrophage-derived exosomes induce dual inhibition of Aβ aggregation and astrocyte activation to alleviate cognitive impairment in a model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Biomimetics; Cognitive Dysfunction; Disease Models, Animal; Exosomes; Macrophages; Mice; Neurodegenerative Diseases; Silybin | 2021 |
Topics: Acute Lung Injury; Adherens Junctions; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antigens, CD; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; beta Catenin; Brain Ischemia; Cadherins; Carcinogenesis; Catalysis; Cell Line; Cells, Cultured; Curcuma; Curcumin; Dioxoles; Disease Models, Animal; Endothelial Cells; Epithelial Cells; Heme Oxygenase (Decyclizing); Humans; Inflammasomes; Intestinal Diseases; Intestinal Mucosa; Ischemic Stroke; Kidney Neoplasms; Lignans; Lung; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; NAD(P)H Dehydrogenase (Quinone); Nanostructures; NF-E2-Related Factor 2; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Pneumonia; PPAR gamma; Proto-Oncogene Proteins c-akt; Pyroptosis; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reperfusion Injury; Respiratory Distress Syndrome; Sepsis; Sesamum; Signal Transduction; Silybin; Silybum marianum; Silymarin; Sirtuin 3; Titanium; Transfection; Treatment Outcome; White Matter | 2021 |
Comparative effects of estrogen and silibinin on cardiovascular risk biomarkers in ovariectomized rats.
Topics: Animals; Disease Models, Animal; Endothelium, Vascular; Estrogens; Female; Humans; Lipid Metabolism; Nitric Oxide; Nitric Oxide Synthase Type III; Ovariectomy; Oxidative Stress; Postmenopause; Rats; Rats, Wistar; Silybin | 2022 |
Silymarin prevents iron overload induced bone loss by inhibiting oxidative stress in an ovariectomized animal model.
Topics: Alkaline Phosphatase; Animals; Antioxidants; Cell Differentiation; Disease Models, Animal; Iron Overload; Osteoblasts; Osteogenesis; Oxidative Stress; Rats; Silybin; Silymarin; Sirtuin 1 | 2022 |
Inhibition of GluN2B pathway is involved in the neuroprotective effect of silibinin on streptozotocin-induced Alzheimer's disease models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats; Receptors, N-Methyl-D-Aspartate; Silybin; Streptozocin | 2023 |
Polyunsaturated fatty acids drive neutrophil extracellular trap formation in nonalcoholic steatohepatitis.
Topics: Animals; Disease Models, Animal; Extracellular Traps; Fatty Acids, Unsaturated; Inflammation; Mice; Neutrophils; Non-alcoholic Fatty Liver Disease; Silybin | 2023 |
Silibinin ameliorates STING-mediated neuroinflammation via downregulation of ferroptotic damage in a sporadic Alzheimer's disease model.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Down-Regulation; Mice; Neuroinflammatory Diseases; Neuroprotective Agents; Rats; Silybin; Streptozocin | 2023 |
Oral Administration of Silybin Protects Against MPTP-Induced Neurotoxicity by Reducing Pro-inflammatory Cytokines and Preserving BDNF Levels in Mice.
Topics: Administration, Oral; Animals; Brain-Derived Neurotrophic Factor; Cytokines; Disease Models, Animal; Dopamine; Mice; MPTP Poisoning; Neurodegenerative Diseases; Silybin | 2023 |
Combined Amphiphilic Silybin Meglumine Nanosuspension Effective Against Hepatic Fibrosis in Mice Model.
Topics: Animals; Biological Availability; Collagen Type I; Disease Models, Animal; Liver Cirrhosis; Meglumine; Mice; Silybin | 2023 |
Silibinin attenuates high-fat diet-induced renal fibrosis of diabetic nephropathy.
Topics: Animals; Apoptosis; Cell Survival; Diabetic Nephropathies; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Fibrosis; Humans; Kidney Glomerulus; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Silybin; Transforming Growth Factor beta1 | 2019 |
Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model.
Topics: Animals; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Lipid Metabolism; Liver; Male; Metabolomics; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Silybin; Taurochenodeoxycholic Acid | 2020 |
Silibinin attenuates adipose tissue inflammation and reverses obesity and its complications in diet-induced obesity model in mice.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Body Weight; Diet, High-Fat; Disease Models, Animal; Gene Expression; Glucose; Hypertrophy; Liver; Male; Mice, Inbred C57BL; Obesity; Silybin | 2020 |
Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.
Topics: Animals; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Renal Insufficiency, Chronic; Signal Transduction; Silybin; Transforming Growth Factor beta1; Valsartan | 2020 |
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Isoquinolines; Mice; Nanoparticles; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Silybin; Tumor Microenvironment | 2020 |
Silibinin treatment results in reducing OPA1&MFN1 genes expression in a rat model hepatic ischemia-reperfusion.
Topics: Animals; Apoptosis; Disease Models, Animal; Gene Expression; Gene Expression Regulation; GTP Phosphohydrolases; Ischemia; Liver; Male; Membrane Proteins; Mitochondria; Mitochondrial Dynamics; Mitochondrial Membranes; Mitochondrial Proteins; Rats; Rats, Wistar; Reperfusion; Reperfusion Injury; Silybin | 2020 |
Silibinin Upregulates CXCR4 Expression in Cultured Bone Marrow Cells (BMCs) Especially in Pulmonary Arterial Hypertension Rat Model.
Topics: Animals; Biomarkers; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Hemodynamics; Macrophages; Male; Pulmonary Arterial Hypertension; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Silybin; Up-Regulation | 2020 |
Delivery and Anti-Psoriatic Effect of Silibinin-Loaded Polymeric Micelles: An Experimental Study in the Psoriatic Skin Model.
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; Imiquimod; Mice; Micelles; Nanoparticles; Particle Size; Polymers; Psoriasis; Signal Transduction; Silybin; Skin; Skin Absorption; STAT3 Transcription Factor | 2020 |
Co-encapsulation of collagenase type I and silibinin in chondroitin sulfate coated multilayered nanoparticles for targeted treatment of liver fibrosis.
Topics: Animals; Capsules; Cell Line; Chondroitin Sulfates; Collagenases; Disease Models, Animal; Hepatic Stellate Cells; Humans; Hyaluronan Receptors; Liver; Liver Cirrhosis; Mice; Nanoparticles; Silybin | 2021 |
Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Mitophagy; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Silybin; Substantia Nigra | 2021 |
Silybin attenuates LPS-induced lung injury in mice by inhibiting NF-κB signaling and NLRP3 activation.
Topics: Acute Lung Injury; Animals; Cell Line; Cytokines; Disease Models, Animal; Female; Humans; Inflammasomes; Inflammation Mediators; Lipopolysaccharides; Mice; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Silybin; Silymarin | 2017 |
Silibinin treatment prevents endotoxin-induced uveitis in rats in vivo and in vitro.
Topics: Animals; Anterior Eye Segment; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aqueous Humor; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; In Vitro Techniques; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Macrophage Activation; Male; Mice; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Rats, Inbred Lew; RAW 264.7 Cells; Signal Transduction; Silybin; Silymarin; Uveitis | 2017 |
Silibinin Improves TNF-α and M30 Expression and Histological Parameters in Rat Kidneys After Hepatic Ischemia/Reperfusion.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Acute Kidney Injury; Administration, Intravenous; Animals; Antioxidants; Disease Models, Animal; Humans; Keratin-18; Kidney; Liver; Male; Necrosis; Rats; Rats, Wistar; Reperfusion Injury; Silybin; Silybum marianum; Silymarin; Tumor Necrosis Factor-alpha | 2018 |
Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anxiety; Autophagy; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Hippocampus; Indans; Male; Neurons; Neuroprotective Agents; Peptide Fragments; Piperidines; Psychotropic Drugs; Rats, Sprague-Dawley; Receptor, trkB; Signal Transduction; Silybin; Silymarin; Up-Regulation | 2017 |
Antioxidative and Anti-Apoptotic Roles of Silibinin in Reversing Learning and Memory Deficits in APP/PS1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antioxidants; Apoptosis; Disease Models, Animal; Hippocampus; Maze Learning; Memory Disorders; Mice, Transgenic; Oxidative Stress; Silybin; Silymarin | 2017 |
Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury.
Topics: Administration, Intravenous; Animals; Biomarkers; Disease Models, Animal; Drug Evaluation, Preclinical; Fas Ligand Protein; fas Receptor; HMGB1 Protein; Humans; Leukocyte Common Antigens; Liver; Male; Protective Agents; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Silybin; Tissue Distribution | 2018 |
Silibinin alleviates inflammation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes and has a therapeutic effect on arthritis in rats.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arthritis; Autophagy; Cell Differentiation; Cell Survival; Cells, Cultured; Disease Models, Animal; Macrophages; Models, Biological; Rats; Silybin; Synoviocytes; Th17 Cells; Therapeutic Uses | 2018 |
Silibinin exerts antidepressant effects by improving neurogenesis through BDNF/TrkB pathway.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; Disease Models, Animal; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neural Stem Cells; Neurogenesis; Phosphorylation; Protein-Tyrosine Kinases; Signal Transduction; Silybin; Silymarin; Stress, Psychological | 2018 |
Silibinin-induced endoplasmic reticulum stress and mitochondrial dysfunction suppress growth of endometriotic lesions.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Calcium; Cell Cycle; Cell Line; Cell Proliferation; Cytokines; Disease Models, Animal; Endometriosis; Endometrium; Endoplasmic Reticulum Stress; Female; Humans; Inflammation Mediators; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Mitochondria; Mitogen-Activated Protein Kinases; Oxidative Stress; Signal Transduction; Silybin | 2019 |
Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression; Lipid Metabolism; Liver Cirrhosis; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silybin; Treatment Outcome | 2018 |
Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin.
Topics: Animals; Biological Availability; Carbon Tetrachloride; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; Emulsions; Liver Diseases; Male; Mice; Nanoparticles; Poloxamer; Protective Agents; Rabbits; Silybin; Silymarin; Solubility | 2019 |
Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Azoxymethane; Carcinogenesis; Carcinogens; cdc25 Phosphatases; Colitis; Colonic Neoplasms; Dextran Sulfate; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Male; Mice; Mice, Inbred C57BL; Silybin | 2019 |
Silibinin inhibits ultraviolet B radiation-induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/-) mouse model of basal cell carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Bone Morphogenetic Protein 2; Carcinoma, Basal Cell; Chemoprevention; Cyclin D1; Disease Models, Animal; DNA Damage; Mast Cells; Mice; Mice, Transgenic; Patched-1 Receptor; Signal Transduction; Silybin; Skin; Skin Neoplasms; Tumor Suppressor Proteins; Ultraviolet Rays | 2019 |
Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia.
Topics: Animals; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Protective Agents; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Silybin; Treatment Outcome | 2019 |
Natural silibinin modulates amyloid precursor protein processing and amyloid-β protein clearance in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Cognitive Dysfunction; Disease Models, Animal; Down-Regulation; Hippocampus; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Silybin; Up-Regulation | 2019 |
Regulation of gut microbiota in Alzheimer's disease mice by silibinin and silymarin and their pharmacological implications.
Topics: Alzheimer Disease; Animals; Antioxidants; Bacteria; Biodiversity; Disease Models, Animal; Gastrointestinal Microbiome; Hippocampus; Learning; Male; Mice; Mice, Transgenic; Plaque, Amyloid; Silybin; Silymarin | 2019 |
Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc(-/+) mice.
Topics: Adenoma; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoprevention; Colorectal Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Disease Models, Animal; Female; Genes, APC; Humans; Ki-67 Antigen; Mice; Mice, Knockout; Retinoblastoma Protein; Signal Transduction; Silybin; Silymarin | 2013 |
A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.
Topics: Animals; Biomarkers; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glutathione; Glutathione Peroxidase; Keratin-18; Liver; Male; Malondialdehyde; Mitochondria, Liver; Mitochondrial Proteins; Nitroso Compounds; Oxidative Phosphorylation; Oxidative Stress; Phospholipids; Rats; Rats, Wistar; Silybin; Silymarin; Sulfhydryl Compounds; Thiobarbituric Acid Reactive Substances; Thioredoxins; Time Factors; Tyrosine; Vitamin E | 2013 |
Silibinin inhibits myofibroblast transdifferentiation in human tenon fibroblasts and reduces fibrosis in a rabbit trabeculectomy model.
Topics: Actins; Animals; Antioxidants; Blotting, Western; Cell Movement; Cell Transdifferentiation; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Fibrosis; Humans; Myofibroblasts; Rabbits; Receptors, Transforming Growth Factor beta; Silybin; Silymarin; Tenon Capsule; Trabecular Meshwork; Trabeculectomy; Transforming Growth Factor beta1; Vimentin | 2013 |
The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Models, Animal; Glucose; Mice; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Podocytes; Reactive Oxygen Species; Silybin; Silymarin; Superoxides | 2013 |
Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Fatty Liver; Gerbillinae; Glutathione; Glutathione Peroxidase; Humans; Insulin; Lipids; Liver; Metabolic Syndrome; Obesity; Oxidative Stress; Silybin; Silymarin; Superoxide Dismutase | 2014 |
Silibinin potentially attenuates arsenic-induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats.
Topics: Adenosine Triphosphatases; Animals; Antioxidants; Arsenites; Disease Models, Animal; Dyslipidemias; Heart Diseases; Heme Oxygenase (Decyclizing); Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lipids; Mitochondria, Heart; Myocardium; NADPH Oxidases; NF-E2-Related Factor 2; Oxidative Stress; Rats; Silybin; Silymarin; Sodium Compounds | 2014 |
Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.
Topics: Animals; Antioxidants; Apoptosis; Calcium-Binding Proteins; Carcinoma, Hepatocellular; Caspase 3; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Models, Animal; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Liver Neoplasms; Male; Membrane Proteins; Mice; Mitochondria; Reactive Oxygen Species; Receptors, Notch; RNA Interference; Serrate-Jagged Proteins; Signal Transduction; Silybin; Silymarin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Female; Inflammation; Interleukin-1beta; Microglia; Nerve Degeneration; Neuroprotective Agents; Nitric Oxide Synthase Type II; Parkinson Disease; Rats; Rats, Sprague-Dawley; Silybin; Silymarin; Substantia Nigra; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2014 |
Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.
Topics: Allografts; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Carcinoma, Basal Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Enzyme Activation; Humans; Mice; Mice, Knockout; NF-kappa B; Signal Transduction; Silybin; Silymarin; Skin Neoplasms; Transcription Factor AP-1; Transcription Factors; Tumor Stem Cell Assay | 2016 |
A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Allografts; Animals; Disease Models, Animal; Drug Resistance; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Pituitary ACTH Hypersecretion; Protein Folding; Receptors, Glucocorticoid; Silybin; Silymarin | 2015 |
Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization.
Topics: Actins; Animals; Antioxidants; Calcium-Binding Proteins; Cell Death; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Dopaminergic Neurons; Embryo, Mammalian; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Mitochondria; Mitochondrial Trifunctional Protein; Motor Activity; MPTP Poisoning; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Silybin; Silymarin | 2015 |
Silibinin suppresses astroglial activation in a mouse model of acute Parkinson's disease by modulating the ERK and JNK signaling pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Antioxidants; Astrocytes; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Rats, Sprague-Dawley; Silybin; Silymarin; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Curcumin, Silybin Phytosome(®) and α-R-Lipoic Acid Mitigate Chronic Hepatitis in Rat by Inhibiting Oxidative Stress and Inflammatory Cytokines Production.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antioxidants; Curcumin; Cytokines; Disease Models, Animal; Hepatitis, Chronic; Male; Oxidative Stress; Rats; Rats, Wistar; Silybin; Silymarin; Thioacetamide; Thioctic Acid | 2016 |
Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
Topics: Administration, Intravenous; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Gene Expression Profiling; Hepacivirus; Hepatitis C; Humans; Liver; Mice, SCID; Microarray Analysis; Models, Theoretical; RNA, Viral; Sequence Analysis, DNA; Serum Albumin; Silybin; Silymarin; Treatment Outcome; Viral Load | 2016 |
Prophylactic Administration of Silybin Ameliorates L-Arginine-Induced Acute Pancreatitis.
Topics: Acute Disease; Animals; Antioxidants; Arginine; Disease Models, Animal; Female; Oxidative Stress; Pancreatitis; Rats; Rats, Wistar; Silybin; Silymarin | 2016 |
Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice.
Topics: Animals; Camellia sinensis; Disease Models, Animal; Humans; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Plant Extracts; Silybin; Silymarin; Sterol Regulatory Element Binding Protein 1; Tea; Transcription Factors | 2017 |
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Body Weight; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasm Staging; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Acute liver acetaminophen toxicity in rabbits and the use of antidotes: a metabonomic approach in serum.
Topics: Acetaminophen; Acetylcysteine; Acute Disease; Alanine Transaminase; Animals; Antidotes; Aspartate Aminotransferases; Biomarkers; Chemical and Drug Induced Liver Injury; Cimetidine; Disease Models, Animal; Liver; Magnetic Resonance Spectroscopy; Male; Rabbits; Silybin; Silymarin | 2009 |
Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
Topics: alpha-Fetoproteins; Animals; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Dietary Supplements; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Histones; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Repressor Proteins; Silybin; Silymarin; Superoxide Dismutase; Superoxide Dismutase-1; Survivin; Transplantation, Heterologous | 2009 |
Silibinin attenuates mast cell-mediated anaphylaxis-like reactions.
Topics: Anaphylaxis; Animals; Anti-Allergic Agents; Calcium; Cell Nucleus; Cell Survival; Cells, Cultured; Cytosol; Disease Models, Animal; Histamine Release; Interleukin-6; Male; Mast Cells; Mice; Mice, Inbred ICR; NF-kappa B; Rats; Rats, Sprague-Dawley; Silybin; Silymarin; Tumor Necrosis Factor-alpha | 2009 |
Silibinin modulates biotransforming microbial enzymes and prevents 1,2-dimethylhydrazine-induced preneoplastic changes in experimental colon cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Bacteria; Body Weight; Colon; Colonic Neoplasms; Disease Models, Animal; Male; Precancerous Conditions; Rats; Rats, Wistar; Silybin; Silymarin | 2009 |
Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway.
Topics: Adenomatous Polyposis Coli Protein; Animals; Antioxidants; beta Catenin; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Immunohistochemistry; Intestinal Neoplasms; Male; Mice; Mutation; Signal Transduction; Silybin; Silymarin | 2009 |
Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin.
Topics: Adenomatous Polyposis Coli; Animals; Antioxidants; Apoptosis; beta Catenin; Cell Growth Processes; Colorectal Neoplasms; Cyclin D1; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Intestinal Polyps; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Silybin; Silymarin; Transcriptional Activation | 2010 |
Silibinin induces the generation of nitric oxide in human breast cancer MCF-7 cells.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Caenorhabditis elegans; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Leukocytes, Mononuclear; Mice; Nitric Oxide; Oxidative Stress; Reactive Nitrogen Species; Reactive Oxygen Species; Silybin; Silymarin; Time Factors; Tumor Cells, Cultured | 2010 |
The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Colitis; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Male; NF-kappa B; Rats; Rats, Wistar; Silybin; Silymarin; Trinitrobenzenesulfonic Acid; Ursodeoxycholic Acid | 2011 |
Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment.
Topics: Acetylcholinesterase; Adenosine Triphosphate; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antioxidants; Brain; Calcium; Disease Models, Animal; Drug Evaluation, Preclinical; Energy Metabolism; Glutathione; Male; Malondialdehyde; Maze Learning; Memory Disorders; Mice; Motor Activity; Oxidative Stress; Reactive Nitrogen Species; Reactive Oxygen Species; Receptors, Nicotinic; Silybin; Silymarin; Streptozocin; Synaptosomes | 2011 |
Effect of silybin on high-fat-induced fatty liver in rats.
Topics: Animals; Antioxidants; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Fatty Liver; Homeostasis; Hypoglycemic Agents; Insulin Resistance; Lipid Peroxidation; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Silymarin; Thiazolidinediones | 2011 |
Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice.
Topics: Acetylcholine; Animals; Antioxidants; Aorta; Arginine; Diabetes Mellitus; Disease Models, Animal; Endothelium, Vascular; Insulin Resistance; Liver; Male; Mice; Mice, Obese; Nitroprusside; Obesity; Phenylephrine; Silybin; Silymarin; Vasoconstrictor Agents; Vasodilator Agents | 2011 |
Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Male; Organoplatinum Compounds; Oxaliplatin; Oxidative Stress; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Silybin; Silymarin | 2012 |
Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Choline Deficiency; Disease Models, Animal; Fatty Liver; Homeostasis; Lipid Metabolism; Liver; Male; Methionine; Mice; Mice, Obese; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silybin; Silymarin; Translational Research, Biomedical | 2012 |
Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Silybin; Silymarin; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Hepatoprotective and anti-inflammatory effects of silibinin on experimental preeclampsia induced by L-NAME in rats.
Topics: Animals; Anti-Inflammatory Agents; Blood Pressure; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Immunologic Factors; Inflammation; Liver; NG-Nitroarginine Methyl Ester; Pre-Eclampsia; Pregnancy; Protective Agents; Rats; Rats, Wistar; Silybin; Silymarin | 2012 |
Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway.
Topics: Angiogenesis Inhibitors; Animals; Autophagy; Blotting, Western; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Epithelial Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Macular Degeneration; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred BN; Retinal Pigment Epithelium; Signal Transduction; Silybin; Silymarin; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2013 |
Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice.
Topics: Adenoma; Administration, Oral; Animals; Benzo(a)pyrene; Disease Models, Animal; Lung Neoplasms; Mice; Mice, Inbred A; Rotenone; Silybin; Silybum marianum; Silymarin | 2005 |
Effect of silibinin on the growth and progression of primary lung tumors in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinogens; Cell Proliferation; Cyclin D1; Cyclooxygenase 2; Disease Models, Animal; Fibroblast Growth Factor 2; Immunohistochemistry; Inflammation; Lung Neoplasms; Mice; Microcirculation; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Silybin; Silymarin; Urethane; Vascular Endothelial Growth Factor A | 2006 |
Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells.
Topics: Animals; Antigen Presentation; Antigens, Surface; Cell Differentiation; Cells, Cultured; Dendritic Cells; Dermatitis, Contact; Disease Models, Animal; Dose-Response Relationship, Drug; Endocytosis; Immunity, Cellular; Immunosuppression Therapy; Immunosuppressive Agents; Interleukin-12; Lectins, C-Type; Male; Mannose Receptor; Mannose-Binding Lectins; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Receptors, Cell Surface; Silybin; Silymarin; T-Lymphocytes, Helper-Inducer; Th1 Cells; Th2 Cells; Transcription Factor RelA | 2007 |
Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model.
Topics: Acetylcysteine; Alanine Transaminase; Amanitins; Animals; Antidotes; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cimetidine; Disease Models, Animal; Male; Mice; Mushroom Poisoning; Penicillin G; Random Allocation; Silybin; Silymarin; Thioctic Acid | 2007 |
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antioxidants; Disease Models, Animal; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Prostate; Prostatic Neoplasms; Silybin; Silymarin; Species Specificity | 2007 |
Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Disease Models, Animal; Glucose; Glutathione; In Vitro Techniques; Lipid Peroxidation; Liver; Liver Transplantation; Male; Medicine, Traditional; Mitochondria, Liver; Oxidative Stress; Rats; Rats, Wistar; Reperfusion Injury; Seeds; Silybin; Silybum marianum; Silymarin; Superoxides; Tromethamine | 2008 |